Accessed at www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
At the same time, the findings for clinical studies were more mixed, and long-term trials showed the possibility of a lower dementia risk with these drugs, but shorter trials did not show consistent cognitive improvements
Improved kidney function: Recent developments in the management of T2D have identified the use of GLP-1s to reduce the progression of kidney disease in individuals with diabetes
In April 2005 the US Food and Drugs Administration (FDA) approved a synthetic version, called exenatide, to treat type 2 diabetic patients unable to sufficiently control their blood sugar levels with other diabetic medications like metformin, and sulfonylureas
While many people have found success with GLP-1s, others whove taken these diabetes and weight loss medications have experienced severe side effects
Characterizing dual GLP-1/GIP receptor agonists demands tools that resolve receptor engagement with specificity and spatial resolution that conventional approaches cannot provide
